In the first quarter of 2025, Jasper Therapeutics made significant strides with briquilimab, particularly in advancing it towards crucial data releases scheduled for later this year. According to Ronald Martell, the President and CEO, the updated findings from the BEACON study in chronic spontaneous urticaria (CSU) showcased briquilimab’s unique quick action, effectiveness, and tolerability. A further update is expected in the first half of the third quarter, featuring more CSU patient data from the BEACON study and its open-label extension. These findings will aid in determining the final dosage for an upcoming Phase 2b study, projected to start in the fourth quarter of 2025.
Additionally, the company plans to unveil more data from the SPOTLIGHT study focused on chronic inducible urticaria (CIndU) during the second quarter. In the latter half of 2025, initial results from the ETESIAN study on asthma will also be shared. Jasper (JSPR, Financial) is on track to provide comprehensive insights that could significantly impact the future of treatments in these therapeutic areas.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $50.63 with a high estimate of $80.00 and a low estimate of $15.00. The average target implies an upside of 968.04% from the current price of $4.74. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
